Company intelligence / Profile preview
Presidio Pharmaceuticals
San Francisco, California, United Statespresidiopharma.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
Presidio Pharmaceuticals has developed a pipeline of small-molecule antiviral drugs targeting hepatitis C and HIV. Its lead HCV program includes PPI‑461, an NS5A inhibitor that showed positive results in a Phase 1b trial for chronic hepatitis C genotype 1 patients—demonstrating good tolerability and significant reductions in HCV RNA levels. Other programs include compounds targeting the HCV NS5B polymerase and investigational therapies for HIV. Some pipeline assets have been discontinued or are pending further development.[6][8]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeAntiviral therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Presidio Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Presidio Pharmaceuticals.